Polymer Factory Sweden AB: Update on financial targets for the fiscal year 2023

Polymer Factory Sweden AB ("Polymer Factory" or the "Company") will adjust its financial targets for the fiscal year 2023. The reason for the change is an update in timelines for projects that were estimated to move forward in late 2023. These projects are instead anticipated for early 2024. The previously communicated financial target of net sales of approx. SEK 3.6 million will be adjusted to an operating income of approx. SEK 2.7 million.

Polymer Factory has during 2023 taken many steps forward towards realizing commercial projects with customers and partners, in accordance with its plan for the year; however, as emphasized in interim reports, lead times for projects in the life science sector are often long and dependent on the customers’ project timelines. The reduction in turnover is not related to a single event and is not considered to deviate from the financial reporting in previously released interim reports.

The Company emphasizes that the adjusted target is indicative, as no financial statements have yet been completed.

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-12-2023 10:03 CET.

For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.